1Grant of Option. In consideration of Participant’s agreement to commence employment with and remain in the employ of the Company or an Affiliate and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the “Grant Date”), the Company has granted to Participant the Option to purchase any part or all of an aggregate of the number of shares of Common Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice and this Agreement. The Option shall be a Non-Qualified Stock Option.
1Grant of Option. The Company hereby grants to the Participant an option (the “Option”) to purchase the total number of shares of Common Stock of the Company equal to the number of Option Shares set forth above, at the Exercise Price set forth above. The Option is being granted pursuant to the Medicine Man Technologies, Inc. 2017 Equity Incentive Plan (the “Plan”).
1Grant of Option. In consideration of the Employee's agreement to remain in the employ of the Company or its Subsidiaries and for other good and valuable consideration, the Company irrevocably grants to the Employee the option to purchase any part or all of an aggregate of 10,500 shares of its Common Stock upon the terms and conditions set forth in this Agreement.
1Grant of Option. In consideration of Participant’s past and/or continued employment with or service to any Company Group Member and for other good and valuable consideration, effective as of the grant date set forth in the Grant Notice (the “Grant Date”), the Company has granted to Participant the Option to purchase any part or all of an aggregate number of Shares set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan and this Agreement, subject to adjustment as provided in Section 12.2 of the Plan.
1Grant of Option. Subject to and conditioned upon the payment by the Purchaser of the additional sum of $25,000 (the Option Purchase Price), at the Initial Block 1 Closing set forth in Section 2.2 above, the Company shall grant to the Purchaser, an Option to purchase an additional 3,579,014 restricted shares of common stock (the Option Shares”). The $25,000 Option Purchase Price is the consideration for the Option and shall be non-refundable and shall not be applied to the purchase of any Block 1 Shares or Option Shares. Exhibit 10.01
1Grant of Option. Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, Paragon hereby grants to Apogee, during the Term and subject to delivery of the Election Notice in accordance with Section 4.4, an exclusive option (“Option”), to be granted an exclusive license to all of Paragon’s right, title and interest in and to the Project Antibody Technology under the applicable Research Program to Develop, Manufacture and Commercialize Project Antibodies, Derived Antibodies and Products in the Field in the Territory.
1Grant of Option. In consideration of the Optionee’s past and/or continued employment with or service to the Company or any Affiliate and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the “Grant Date”), the Company grants to the Optionee the Option to purchase any part or all of the aggregate number of Shares set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement.
1Grant of Option. Subject to the terms and conditions of this Agreement, TMRI hereby grants to BMET USA the sole, exclusive and irrevocable right for BMETUSA to acquire all of the issued and outstanding SMMI Shares ("Option") free and clear of any Encumbrance on Completion.
1Grant of Option. With respect to each of the AML Program and the Collaboration Program for the Second Additional Collaboration Target (if any), BMS hereby grants to Century the option to, at Century’s cost and expense, to elect to conduct [***] ([***]%) (but no less or more than [***] ([***]%)) of the detailing effort with respect to Products from such Collaboration Program in the United States (each, a “Co-Promote Option”). BMS will keep Century reasonably informed of the planned Commercialization of such Products, as applicable, in the Field in the Territory, and, no later than [***] months prior to the date that is reasonably expected for the first Approval for the first indication for a Co-Promotion Product from the applicable Collaboration Program in the U.S., provide Century with written notice thereof (each, an “Co-Promotion Option Notice”). Century may exercise the applicable Co-Promote Option by providing written notice to BMS within [***] following Century’s receipt of the applicable Co-Promotion Option Notice (the “Co-Promote Opt-in Deadline”). If Century does not exercise such Co-Promote Option prior to the applicable Co-Promote Opt-in Deadline, or in the event of any Change of Control of Century (or any of its controlling Affiliates) prior to Century’s exercise of the applicable Co-Promote Option as provided for in Section 6.3.2, the Co-Promote Option will expire, and Century shall have no further rights with respect to such Co-Promote Option.
1Grant of Option. On a Selected Fc Antibody-by-Selected Fc Antibody basis, subject to the terms and conditions of this Agreement, Xencor hereby grants to Omeros an exclusive option to obtain a Commercial License with respect to each Selected Fc Antibody ( including Derivative Fc Antibody(ies) thereof) on the terms set forth in Section 3.3 (each, an “Option”).
